Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFARUNASDAQ:AFARWOTCMKTS:AVPIOTCMKTS:ENZC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFARUAura FAT Projects Acquisition$12.74$12.74$11.41▼$15.59N/AN/A3,767 shsN/AAFARWAura FAT Projects Acquisition$0.03$0.03$0.01▼$0.05N/AN/A20,407 shsN/AAVPIAVP$0.00$0.00▼$0.00N/AN/AN/AN/AENZCEnzolytics$0.00+14.3%$0.00$0.00▼$0.01N/AN/A4.67 million shs1.24 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFARUAura FAT Projects Acquisition0.00%0.00%0.00%0.00%+16.43%AFARWAura FAT Projects Acquisition0.00%0.00%0.00%0.00%+121.54%AVPIAVP0.00%0.00%0.00%0.00%0.00%ENZCEnzolytics+14.29%+33.33%+14.29%-11.11%-84.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFARUAura FAT Projects AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAFARWAura FAT Projects AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAVPIAVPN/AN/AN/AN/AN/AN/AN/AN/AENZCEnzolyticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFARUAura FAT Projects Acquisition 0.00N/AN/AN/AAFARWAura FAT Projects Acquisition 0.00N/AN/AN/AAVPIAVP 0.00N/AN/AN/AENZCEnzolytics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFARUAura FAT Projects AcquisitionN/AN/AN/AN/AN/AN/AAFARWAura FAT Projects AcquisitionN/AN/AN/AN/AN/AN/AAVPIAVPN/AN/AN/AN/AN/AN/AENZCEnzolyticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFARUAura FAT Projects AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAFARWAura FAT Projects AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAVPIAVPN/AN/A0.00N/AN/AN/AN/AN/AN/AENZCEnzolyticsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFARUAura FAT Projects AcquisitionN/AN/AN/AN/AN/AAFARWAura FAT Projects AcquisitionN/AN/AN/AN/AN/AAVPIAVPN/AN/AN/AN/AN/AENZCEnzolyticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFARUAura FAT Projects AcquisitionN/AAFARWAura FAT Projects AcquisitionN/AAVPIAVPN/AENZCEnzolyticsN/AInsider OwnershipCompanyInsider OwnershipAFARUAura FAT Projects AcquisitionN/AAFARWAura FAT Projects AcquisitionN/AAVPIAVP37.00%ENZCEnzolyticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFARUAura FAT Projects Acquisition2N/AN/ANot OptionableAFARWAura FAT Projects Acquisition2N/AN/ANot OptionableAVPIAVP32N/AN/ANot OptionableENZCEnzolytics2N/AN/ANot OptionableENZC, AFARW, AFARU, and AVPI HeadlinesRecent News About These CompaniesBulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an ImmunomodulatorSeptember 18, 2024 | accesswire.comDepartment of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year AgreementSeptember 9, 2024 | accesswire.comFinal Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer CellsAugust 20, 2024 | accesswire.comEnzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS ApplicationsJuly 31, 2024 | accesswire.comEnzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.July 29, 2024 | accesswire.comEnzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press ReleaseJuly 26, 2024 | accesswire.comEnzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer TreatmentJuly 1, 2024 | accesswire.comEnzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD TechnologyJune 3, 2024 | accesswire.comEnzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast FulfillmentMay 2, 2024 | accesswire.comEnzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in NevadaApril 23, 2024 | accesswire.comEnzolytics, Inc. (ENZC)April 19, 2024 | finance.yahoo.comEnzolytics, Inc.: Update on Formulation of New Business StrategyApril 12, 2024 | finanznachrichten.deUpdate on Formulation of New Business StrategyApril 12, 2024 | accesswire.comENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARDMarch 25, 2024 | finance.yahoo.comEnzolytics Stock (OTC:ENZC) Insider TradesFebruary 26, 2024 | benzinga.comEnzolytics Stock (OTC:ENZC) Earnings Dates and Earning CallsFebruary 22, 2024 | benzinga.comEnzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on LongevityJanuary 16, 2024 | finance.yahoo.comEnzolytics Inc ENZCNovember 11, 2023 | morningstar.com"Exploring Penny Stocks: Four Watchlist Options" FTRS, ELTP, ENZC, ZOMOctober 31, 2023 | benzinga.comEnzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)September 18, 2023 | finance.yahoo.comENZC, AFARW, AFARU, and AVPI Company DescriptionsAura FAT Projects Acquisition NASDAQ:AFARU$12.74 0.00 (0.00%) As of 03/13/2025Aura FAT Projects Acquisition Corp does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring technology companies with Web 3.0, blockchain, cryptocurrency, digital ledger, e-gaming, and other new financial technology and services applications in Southeast Asia, Australia, and New Zealand. The company was incorporated in 2021 and is based in Singapore.Aura FAT Projects Acquisition NASDAQ:AFARW$0.03 0.00 (0.00%) As of 03/13/2025Aura FAT Projects Acquisition Corp does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring technology companies with Web 3.0, blockchain, cryptocurrency, digital ledger, e-gaming, and other new financial technology and services applications in Southeast Asia, Australia, and New Zealand. The company was incorporated in 2021 and is based in Singapore.AVP OTCMKTS:AVPIAVP, Inc. produces, markets, and distributes volleyball events worldwide. The company was founded in 1983 and is based in Los Angeles, California.Enzolytics OTCMKTS:ENZC$0.0008 +0.00 (+14.29%) As of 05/2/2025 03:22 PM EasternEnzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
